APOL1, Sickle Cell Trait, and CKD in the Jackson Heart Study

2019 Brancati, 1992, Patient characteristics related to intensity of weight reduction care in a university medical clinic, J Gen Intern Med, 7, 609, 10.1007/BF02599199 Brancati, 1997, Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial, JAMA, 278, 2069, 10.1001/jama.1997.03550230045035 Choi, 2009, White/black racial differences in risk of end-stage renal disease and death, Am J Med, 122, 672, 10.1016/j.amjmed.2008.11.021 Brancati, 1992, The excess incidence of diabetic end-stage renal disease among blacks. A population-based study of potential explanatory factors [see comments], JAMA, 268, 3079, 10.1001/jama.1992.03490210061036 Pollak, 2012, APOL1 and kidney disease, Curr Opin Nephrol Hypertens, 21, 179, 10.1097/MNH.0b013e32835012ab Genovese, 2010, Association of trypanolytic ApoL1 variants with kidney disease in African Americans, Science, 329, 841, 10.1126/science.1193032 Anders, 2016, A pathophysiology-based approach to the diagnosis and treatment of lupus nephritis, Kidney Int, 90, 493, 10.1016/j.kint.2016.05.017 Foster, 2013, APOL1 variants associate with increased risk of CKD among African Americans, J Am Soc Nephrol, 24, 1484, 10.1681/ASN.2013010113 Grams, 2016, Race, APOL1 risk, and eGFR decline in the general population, J Am Soc Nephrol, 27, 2842, 10.1681/ASN.2015070763 2008, Registry shows in-center nocturnal most popular, Nephrol News Issues, 22, 42 Kanji, 2011, Genetic variation in APOL1 associates with younger age at hemodialysis initiation, J Am Soc Nephrol, 22, 2091, 10.1681/ASN.2010121234 Tzur, 2012, APOL1 allelic variants are associated with lower age of dialysis initiation and thereby increased dialysis vintage in African and Hispanic Americans with non-diabetic end-stage kidney disease, Nephrol Dial Transplant, 27, 1498, 10.1093/ndt/gfr796 Reeves-Daniel, 2011, The APOL1 gene and allograft survival after kidney transplantation, Am J Transplant, 11, 1025, 10.1111/j.1600-6143.2011.03513.x Friedman, 2011, Population-based risk assessment of APOL1 on renal disease, J Am Soc Nephrol, 22, 2098, 10.1681/ASN.2011050519 Wasser, 2012, Population genetics of chronic kidney disease: the evolving story of APOL1, J Nephrol, 25, 603 Naik, 2014, Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans, JAMA, 312, 2115, 10.1001/jama.2014.15063 Taylor, 2005, The Jackson Heart Study: an overview, Ethn Dis, 15, S6-1 Taylor, 2012, The Jackson Heart Study of the future, Ethn Dis, 22, S1-49 Fuqua, 2005, Recruiting African-American research participation in the Jackson Heart Study: methods, response rates, and sample description, Ethn Dis, 15, S6-18 Wang, 2015, Effects of serum creatinine calibration on estimated renal function in African Americans: the Jackson Heart Study, Am J Med Sci. March, 349, 279 Ito, 2014, Increased burden of cardiovascular disease in carriers of APOL1 genetic variants, Circ Res, 114, 845, 10.1161/CIRCRESAHA.114.302347 Bick, 2012, Burden of rare sarcomere gene variants in the Framingham and Jackson Heart Study cohorts, Am J Human Genet, 91, 513, 10.1016/j.ajhg.2012.07.017 Carpenter, 2004, Laboratory, reading center, and coordinating center data management methods in the Jackson Heart Study, Am J Med Sci, 328, 131, 10.1097/00000441-200409000-00001 Levey, 2009, A new equation to estimate glomerular filtration rate, Ann Intern Med, 150, 604, 10.7326/0003-4819-150-9-200905050-00006 Shlipak, 2009, Rapid decline of kidney function increases cardiovascular risk in the elderly, J Am Soc Nephrol, 20, 2625, 10.1681/ASN.2009050546 Coresh, 2014, Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality, JAMA, 311, 2518, 10.1001/jama.2014.6634 Young, 2016, Risk factors for rapid kidney function decline among African Americans: the Jackson Heart Study (JHS), Am J Kidney Dis, 68, 229, 10.1053/j.ajkd.2016.02.046 Tzur, 2010, Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene, Hum Genet, 128, 345, 10.1007/s00439-010-0861-0 Parsa, 2013, APOL1 risk variants, race, and progression of chronic kidney disease, N Engl J Med, 369, 2183, 10.1056/NEJMoa1310345 Mukamal, 2016, APOL1 genotype, kidney and cardiovascular disease, and death in older adults, Arterioscler Thromb Vasc Biol, 36, 398, 10.1161/ATVBAHA.115.305970 Chen, 2015, Examination of potential modifiers of the association of APOL1 alleles with CKD progression, Clin J Am Soc Nephrol, 10, 2128, 10.2215/CJN.05220515 Peralta, 2016, APOL1 genotype and race differences in incident albuminuria and renal function decline, J Am Soc Nephrol, 27, 887, 10.1681/ASN.2015020124 Olabisi, 2016, APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases, Proc Natl Acad Sci U S A, 113, 830, 10.1073/pnas.1522913113 O'Toole, 2017, The cell biology of APOL1, Semin Nephrol, 37, 538, 10.1016/j.semnephrol.2017.07.007 Pollak, 2017, Introduction: APOL1-associated kidney disease, Semin Nephrol, 37, 489, 10.1016/j.semnephrol.2017.07.001